Guilherme Nader Marta, Clinical Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Great PROs presentation from ASCENT-04 by Evandro de Azambuja at ESMO25
ASCENT-04, SG+pembro maintained QoL vs chemo+pembro in PD-L1+ mTNBC, with improved emotional function (HR 0.71), less pain (0.75) and insomnia (0.75), consistent safety profile.”
Follow the latest ESMO 2025 news on OncoDaily.
